GT201400303A - Purificación de iduronato-2- sulfatasa - Google Patents

Purificación de iduronato-2- sulfatasa

Info

Publication number
GT201400303A
GT201400303A GT201400303A GT201400303A GT201400303A GT 201400303 A GT201400303 A GT 201400303A GT 201400303 A GT201400303 A GT 201400303A GT 201400303 A GT201400303 A GT 201400303A GT 201400303 A GT201400303 A GT 201400303A
Authority
GT
Guatemala
Prior art keywords
iduronate
sulfatase
purification
protein
sorpressive
Prior art date
Application number
GT201400303A
Other languages
English (en)
Spanish (es)
Inventor
Dave Nichols
Original Assignee
Shire Human Genetic Therapies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49778401&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201400303(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Human Genetic Therapies filed Critical Shire Human Genetic Therapies
Publication of GT201400303A publication Critical patent/GT201400303A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
GT201400303A 2012-06-29 2014-12-29 Purificación de iduronato-2- sulfatasa GT201400303A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261666733P 2012-06-29 2012-06-29

Publications (1)

Publication Number Publication Date
GT201400303A true GT201400303A (es) 2017-08-31

Family

ID=49778401

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201400303A GT201400303A (es) 2012-06-29 2014-12-29 Purificación de iduronato-2- sulfatasa

Country Status (38)

Country Link
US (6) US9051556B2 (fi)
EP (2) EP2867245B1 (fi)
JP (4) JP6171007B2 (fi)
KR (5) KR101380740B1 (fi)
CN (3) CN107596358A (fi)
AR (1) AR091647A1 (fi)
AU (3) AU2013282395C1 (fi)
BR (1) BR112014032567B1 (fi)
CA (2) CA2877517C (fi)
CL (1) CL2014003567A1 (fi)
CO (1) CO7240396A2 (fi)
CR (1) CR20140588A (fi)
CY (1) CY1121519T1 (fi)
DK (1) DK2867245T3 (fi)
DO (1) DOP2014000294A (fi)
EA (2) EA202090044A1 (fi)
ES (1) ES2689468T3 (fi)
GT (1) GT201400303A (fi)
HK (4) HK1209431A1 (fi)
HR (1) HRP20181897T1 (fi)
HU (1) HUE040769T2 (fi)
IL (4) IL236315A (fi)
LT (1) LT2867245T (fi)
MX (3) MX366906B (fi)
MY (3) MY157087A (fi)
NZ (3) NZ743910A (fi)
PE (1) PE20150720A1 (fi)
PH (3) PH12014502871A1 (fi)
PL (1) PL2867245T3 (fi)
PT (1) PT2867245T (fi)
RS (1) RS58005B1 (fi)
SG (2) SG11201408761VA (fi)
SI (1) SI2867245T1 (fi)
TR (1) TR201815811T4 (fi)
TW (2) TWI553120B (fi)
UA (1) UA121959C2 (fi)
WO (1) WO2014005014A2 (fi)
ZA (2) ZA201409397B (fi)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008282496B2 (en) 2007-07-27 2013-04-04 Armagen Technologies, Inc. Methods and compositions for increasing alpha-iduronidase activity in the CNS
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
KR101158673B1 (ko) 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
MX2019002252A (es) 2016-08-25 2019-07-04 Japan Chem Res Metodo para producir una proteina de fusion de anticuerpo.
CN106282231B (zh) * 2016-09-06 2020-01-03 陕西慧康生物科技有限责任公司 粘多糖贮积症ii型动物模型的构建方法及应用
CN106428420B (zh) * 2016-10-17 2018-08-21 上海江南长兴造船有限责任公司 一种用于超大型集装箱船止裂钢舱口围的安装的方法
CN111278859A (zh) 2017-10-02 2020-06-12 戴纳立制药公司 包含酶替代疗法酶的融合蛋白
WO2020132452A1 (en) * 2018-12-20 2020-06-25 Shire Human Genetic Therapies, Inc. Purification of iduronate-2-sulfatase immunoglobulin fusion protein
CA3173820A1 (en) * 2020-10-23 2022-04-28 Alexion Pharmaceuticals, Inc. Method of controlling total sialic acid content (tsac) during manufacturing of alkaline phosphatase

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK6488D0 (da) 1988-01-07 1988-01-07 Novo Industri As Enzymer
US5310646A (en) 1988-05-13 1994-05-10 Regents Of The University Of Minnesota Method for the detection of mucopolysaccharide storage diseases
US5932211A (en) * 1991-11-12 1999-08-03 Women's And Children's Hospital Glycosylation variants of iduronate 2-sulfatase
AU700369B2 (en) 1994-03-16 1999-01-07 Regents Of The University Of California, The Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
DE19527054A1 (de) 1995-07-26 1997-01-30 Behringwerke Ag Verfahren zur Charakterisierung der Glycosylierung von Glycoproteinen sowie zur in-vitro Bestimmung der Bioverfügbarkeit von Glycoproteinen
EP2243827B2 (en) 1996-08-30 2017-11-22 Life Technologies Corporation Serum-free mammalian cell culture medium, and uses thereof
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
US7083793B2 (en) 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
EP2301947A3 (en) 1999-02-26 2011-11-23 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
US6506598B1 (en) 1999-04-26 2003-01-14 Genentech, Inc. Cell culture process
JP2002017376A (ja) 1999-07-08 2002-01-22 Herikkusu Kenkyusho:Kk 分泌蛋白質、または膜蛋白質
JP2003508088A (ja) 1999-09-03 2003-03-04 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ５２個のヒト分泌タンパク質
US6780627B1 (en) 2000-01-31 2004-08-24 Millennium Pharmaceuticals, Inc. 22438, 23553, 25278, and 26212 novel human sulfatases
EP1255819A2 (en) 2000-02-17 2002-11-13 Incyte Genomics, Inc. Human kinases
AU2001252917A1 (en) 2000-03-17 2001-10-03 Human Genome Sciences, Inc. 7 human ovarian and ovarian cancer associated proteins
CA2405701A1 (en) 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
US20030148920A1 (en) 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
AU2002317700A1 (en) 2001-06-07 2002-12-16 Hemebiotech A/S Production of recombinant human arylsulfatase a
PT1501369E (pt) 2002-04-26 2015-09-21 Genentech Inc Purificação de proteínas com base na não afinidade
US6890736B1 (en) 2002-09-20 2005-05-10 Immunex Corporation Methods for producing proteins in cultured cells
JP4541157B2 (ja) 2002-12-23 2010-09-08 ブリストル−マイヤーズ スクイブ カンパニー タンパク質を製造するための哺乳類細胞培養法
JP4606712B2 (ja) * 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー ２−ｏスルファターゼ組成物および関連の方法
PT1592786E (pt) 2003-02-11 2012-01-19 Shire Human Genetic Therapies Diagnóstico e tratamento da deficiência de múltiplas sulfatases e outras utilizando uma enzima geradora de formilglicina (fge)
US20050019914A1 (en) 2003-07-24 2005-01-27 Aventis Pharma Deutschland Gmbh Perfusion process for producing erythropoietin
EP2532742B1 (en) 2004-01-30 2018-08-08 Shire Pharmaceuticals Ireland Limited Recombinant arylsulfatase A for reducing galatosyl sulphatide levels in a subject
WO2005113765A2 (en) 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
ES2370417T3 (es) 2005-06-03 2011-12-15 Ares Trading S.A. Producción de una proteína de unión a il-18 recombinante.
US20100190210A1 (en) 2006-03-20 2010-07-29 Medarex, Inc. Protein Purification
JP4458377B2 (ja) 2007-06-29 2010-04-28 キヤノン株式会社 プロセスカートリッジ及び電子写真画像形成装置
US20130195888A1 (en) 2007-11-30 2013-08-01 Abbvie Ultrafiltration and diafiltration formulation methods for protein processing
MX2010007846A (es) * 2008-01-18 2010-10-05 Biomarin Pharm Inc Fabricación de enzimas sulfatasa lisosomal humana altamente fosforilada, activa y usos de las mismas.
PL2485761T3 (pl) 2009-10-09 2019-10-31 Armagen Inc Sposoby i kompozycje do zwiększania aktywności 2-sulfatazy iduronianu w cns
JPWO2011108451A1 (ja) * 2010-03-01 2013-06-27 日本ケミカルリサーチ株式会社 遺伝子ノックアウト細胞を用いた組換え体リソソーム酵素の製造方法
US20110318327A1 (en) * 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc. Treatment of sanfilippo syndrome type b
MX2013000322A (es) 2010-06-25 2013-04-03 Shire Human Genetic Therapies Composiciones y metodos para suministro al sistema nervioso central de iduronato-2-sulfatasa.
AR082319A1 (es) 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
EP2623118A4 (en) * 2010-09-28 2014-05-07 Kyoritsu Seiyaku Corp MUCOSAL ADJUVANT COMPOSITION
WO2012101671A1 (en) * 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
WO2012105954A1 (en) 2011-01-31 2012-08-09 Hewlett-Packard Development Company, L. P. A diffuser with a dynamically tunable scattering angle
KR101158673B1 (ko) 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
KR101380740B1 (ko) * 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
US20140004097A1 (en) 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
KR20190062745A (ko) 2017-11-29 2019-06-07 주식회사 위니플 쇼핑몰 모바일앱 빌더

Also Published As

Publication number Publication date
CN104583225A (zh) 2015-04-29
AR091647A1 (es) 2015-02-18
HK1249026A1 (zh) 2018-10-26
KR20140004603A (ko) 2014-01-13
PL2867245T3 (pl) 2019-02-28
US20210317426A1 (en) 2021-10-14
US20150313972A1 (en) 2015-11-05
CN107596357A (zh) 2018-01-19
JP6505629B2 (ja) 2019-04-24
EP2867245B1 (en) 2018-09-12
IL236315A0 (en) 2015-02-26
MY180287A (en) 2020-11-27
AU2018200230B2 (en) 2020-01-02
CA3008945A1 (en) 2014-01-03
PH12014502871B1 (en) 2015-02-23
BR112014032567A2 (pt) 2017-08-01
JP6171007B2 (ja) 2017-07-26
IL261264A (en) 2018-10-31
IL248727A0 (en) 2017-01-31
TWI587869B (zh) 2017-06-21
TR201815811T4 (tr) 2018-11-21
US9051556B2 (en) 2015-06-09
DK2867245T3 (en) 2018-11-26
PH12014502871A1 (en) 2015-02-23
CY1121519T1 (el) 2020-05-29
KR101380740B1 (ko) 2014-04-11
IL287057A (en) 2021-12-01
HUE040769T2 (hu) 2019-03-28
ES2689468T3 (es) 2018-11-14
MY157087A (en) 2016-04-19
CO7240396A2 (es) 2015-04-17
JP2020105209A (ja) 2020-07-09
TW201410868A (zh) 2014-03-16
KR20140002451A (ko) 2014-01-08
AU2016200469A1 (en) 2016-02-18
HK1209431A1 (en) 2016-04-01
US9492511B2 (en) 2016-11-15
SI2867245T1 (sl) 2018-12-31
IL236315A (en) 2016-11-30
EP2867245A4 (en) 2016-03-09
CA2877517A1 (en) 2014-01-03
CN107596358A (zh) 2018-01-19
JP2015523072A (ja) 2015-08-13
RS58005B1 (sr) 2019-02-28
US11530393B2 (en) 2022-12-20
KR20200143339A (ko) 2020-12-23
ZA201409397B (en) 2019-10-30
MX366906B (es) 2019-07-30
US20140004096A1 (en) 2014-01-02
PE20150720A1 (es) 2015-05-16
WO2014005014A3 (en) 2014-02-27
US10344270B2 (en) 2019-07-09
US20240043817A1 (en) 2024-02-08
SG10201703489VA (en) 2017-05-30
WO2014005014A2 (en) 2014-01-03
MY192068A (en) 2022-07-25
DOP2014000294A (es) 2015-03-15
NZ733366A (en) 2019-12-20
PH12015502408B1 (en) 2018-03-26
AU2013282395A1 (en) 2015-01-29
AU2018200230A1 (en) 2018-02-01
EA201492177A1 (ru) 2015-06-30
US20190359958A1 (en) 2019-11-28
KR20220002227A (ko) 2022-01-06
PH12020500027A1 (en) 2021-03-15
EP3441398A1 (en) 2019-02-13
KR20190064542A (ko) 2019-06-10
EA034549B1 (ru) 2020-02-19
AU2013282395B2 (en) 2015-12-03
IL261264B (en) 2021-10-31
TW201703794A (zh) 2017-02-01
AU2016200469B2 (en) 2017-10-12
HK1249027A1 (zh) 2018-10-26
HK1209767A1 (en) 2016-04-08
JP2018121645A (ja) 2018-08-09
BR112014032567B1 (pt) 2022-09-13
MX2019008914A (es) 2019-09-26
US20170073652A1 (en) 2017-03-16
MX2015000190A (es) 2015-04-08
PH12015502408A1 (en) 2018-03-26
SG11201408761VA (en) 2015-01-29
PT2867245T (pt) 2018-11-26
EA202090044A1 (ru) 2020-07-31
AU2013282395C1 (en) 2016-03-24
CA2877517C (en) 2018-07-31
UA121959C2 (uk) 2020-08-25
EP2867245A2 (en) 2015-05-06
NZ703093A (en) 2017-08-25
LT2867245T (lt) 2018-11-12
CL2014003567A1 (es) 2015-04-24
HRP20181897T1 (hr) 2019-01-11
TWI553120B (zh) 2016-10-11
JP2016119911A (ja) 2016-07-07
CR20140588A (es) 2015-04-06
MX336715B (es) 2016-01-28
NZ743910A (en) 2019-12-20
ZA201803289B (en) 2021-04-28

Similar Documents

Publication Publication Date Title
GT201400303A (es) Purificación de iduronato-2- sulfatasa
SG10201900948PA (en) Modified nucleotide linkers
BRPI0909040A8 (pt) Derivados de azetidina e ciclobutano, seus usos, e composição
CO6501191A2 (es) Medio de cultivo celular para expresión de la proteina adamts
BR112015022292A2 (pt) processo de fabricação escalonável para produzir vetores lentivirais recombinantes em um sistema de cultura celular em suspensão sem soro
CR20140576A (es) Sintesis de compuestos heterociclicos
SMT201600065B (it) Procedimento per la produzione di composti di 177lu altamente puri senza supporto nonché composti di 177lu senza supporto
ECSP14013339A (es) Compuestos con actividad nematicida
ECSP13012978A (es) Inhibidores de glucosilceramida sintasa
CR20140586A (es) Celulas para producir iduronato-2-sulfatasa recombinante
BR112012012008A2 (pt) célula, ácidos nucleicos, enzimas e seu uso bem como processo para a produção de soforolipídios.
EA201390274A1 (ru) Борсодержащие малые молекулы
EA201591106A1 (ru) Цеолитовые адсорбенты, способ их изготовления и их применение
AR093986A1 (es) Cuerpos de carbono ferromagneticos y proceso de produccion
EA201590503A1 (ru) Альфа-1-микроглобулин для применения в лечении заболеваний, связанных с митохондриями
BR112016006865A2 (pt) berberinas substituídas e suas sínteses
IN2014KN02722A (fi)
TR201902152T4 (tr) Metiltioninyum klorür (mtc) bulunan diaminofenotiazinyum bileşiklerinin kimyasal sentezi için yöntemler.
SV2011003784A (es) Nifurtimox para el tratamiento de enfermedades causadas por trichomonadida
BR112013032223A2 (pt) molécula de ácido nucleico isolada, e, composição
NZ709541A (en) Compounds and methods for purification of serine proteases
SMT201500018B (it) Processo ad elevata sicurezza per la preparazione di frazioni purificate di cellule staminali
IL227409A0 (en) Purification of an alpha 1 protease inhibitor obtained from cell culture
BR112015007887A2 (pt) compostos úteis para produzir inibidores hcv protease